Index | Solactive Pharma Breakthrough Value |
Investment focus | Equity, World, Health Care |
Fund size | GBP 14 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 14.48% |
Inception/ Listing Date | 23 January 2018 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Germany | 30% tax rebate |
Switzerland | No ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
Alnylam Pharmaceuticals | 3.90% |
United Therapeutics Corp. | 3.34% |
Halozyme Therapeutics | 3.04% |
Sarepta Therapeutics | 2.98% |
AstraZeneca PLC ADR | 2.93% |
Bavarian Nordic A/S | 2.89% |
Ipsen SA | 2.70% |
Vertex Pharmaceuticals, Inc. | 2.68% |
BioCryst Pharmaceuticals | 2.64% |
CSL Ltd. | 2.59% |
Health Care | 92.14% |
Other | 7.86% |
YTD | -1.46% |
1 month | +1.12% |
3 months | +5.05% |
6 months | +7.55% |
1 year | -4.58% |
3 years | -12.97% |
5 years | +4.37% |
Since inception (MAX) | +13.88% |
2023 | -15.14% |
2022 | +3.96% |
2021 | -2.71% |
2020 | +22.92% |
Volatility 1 year | 14.48% |
Volatility 3 years | 17.17% |
Volatility 5 years | 19.43% |
Return per risk 1 year | -0.32 |
Return per risk 3 years | -0.26 |
Return per risk 5 years | 0.04 |
Maximum drawdown 1 year | -16.49% |
Maximum drawdown 3 years | -28.25% |
Maximum drawdown 5 years | -28.25% |
Maximum drawdown since inception | -28.25% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | ETLI | - - | - - | - |
Borsa Italiana | EUR | BIOT | BIOT IM ETLIEUIV | BIOT.MI ETLIEURINAV=SOLA | Flow Traders B.V. |
Euronext Amsterdam | EUR | BIOT | BIOT NA ETLIEUIV | GOBIOT.AS ETLIEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | BIGT | BIGT LN NA | BIGT.L NA | Flow Traders B.V. |
London Stock Exchange | USD | BIOT | BIOT LN NA | GEBIOT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | BIOT | BIOT SW ETLIEUIV | BIOTC.S ETLIEURINAV=SOLA | Flow Traders B.V. |
XETRA | EUR | ETLI | ETLI GY ETLIEUIV | ETLI.DE ETLIEURINAV=SOLA | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,025 | 0.40% p.a. | Accumulating | Sampling |
L&G Healthcare Breakthrough UCITS ETF USD Acc | 63 | 0.49% p.a. | Accumulating | Full replication |
HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF | 15 | 0.59% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 6 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |